Skip to main content
SpringerLink
Log in

Primary Therapy for Acromegaly with Somatostatin Analogs and a Discussion of Novel Peptide Analogs

  • Original Article
  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Melmed S, Kleinberg D. Anterior pituitary. In: Larsen PR, Kronenberg HM, Melmed S, eds. Williams Textbook of Endocrinology, 10th ed. Philadelphia: Saunders, 2003:177–279.

    Google Scholar 

  2. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM. Octreotide treatment of acromegaly: A randomized, multicenter study. Ann Intern Med 1992;117:711–711.

    CAS  PubMed  Google Scholar 

  3. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF. Safety and efficacy of long term octreotiDe therapy of acromegaly: Results of a multicenter trial in 103 patients—A clinical research center study. J Clin Endocrinol Metab 1995;80:2768–2768.

    Article  CAS  PubMed  Google Scholar 

  4. Newman CB, Melmed S, Snyder P, Young W, Klibanski A, Molitch M, Gagel R, Boyd AE, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Jaffe C, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. 77th Annual Meeting of the Endocrine Society OR4-2. 1995 (Abstract).

  5. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients—A multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133:430–439.

    CAS  PubMed  Google Scholar 

  6. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med 1991;151:1573–1578.

    Article  CAS  PubMed  Google Scholar 

  7. Sassolas G, Harris AG, James-Deidier A. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990;71:391–397.

    CAS  PubMed  Google Scholar 

  8. Cheung NW, Taylor L, Boyages SC. An audit of long-term octreotide therapy for acromegaly. Aust NZ J Med 1997;27:12–18.

    CAS  Google Scholar 

  9. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267–3272.

    CAS  PubMed  Google Scholar 

  10. Lancranjan I, Bruns C, Grass P. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metab 1996;45:67–71.

    CAS  Google Scholar 

  11. Flogstad AK, Halse J, Bakke S. Sandostatin LAR in acromegalic patients: Long term treatment. J Clin Endocrinol Metab 1997;82:23–28.

    Article  CAS  PubMed  Google Scholar 

  12. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311–316.

    Article  CAS  Google Scholar 

  13. Pagani G, Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G, Cortesi L, Pedroncelli A, Tonnarelli GP. Medical management of acromegaly: Effects of SMS 201-995 in 30 patients. Endocrinol Exp 1990;24:175–175.

    CAS  PubMed  Google Scholar 

  14. Tolis G, Yotis A, del Pozo E, Pitoulis S. Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly. J Neurosurg 1986;65:37–40.

    CAS  PubMed  Google Scholar 

  15. Tauber JP, Babin TH, Tauber MT. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 1989;68:917–924.

    CAS  PubMed  Google Scholar 

  16. Sandler LM, Burrin JM, Williams G, Joplin GF, Carr DH, Bloom SR. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995). Clin Endocrinol (Oxf) 1987;26:85–95.

    CAS  Google Scholar 

  17. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ. Preoperative treatment of acromegly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040–1048.

    CAS  PubMed  Google Scholar 

  18. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000;85:4099–4103.

    Article  CAS  PubMed  Google Scholar 

  19. Morange I, De Boisvilliers F, Chanson P, Lucas B, De Wailly D, Catus F, Thomas F, Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endo Metab 1994;79:145–151.

    CAS  Google Scholar 

  20. Cannavo S, Squadrito S, Curto L, Almoto B, Vieni A, Trimarchi F. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 2000;32:224–229.

    CAS  PubMed  Google Scholar 

  21. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 1997;27:277–284.

    Article  CAS  PubMed  Google Scholar 

  22. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721–727.

    Article  CAS  PubMed  Google Scholar 

  23. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20–26.

    CAS  PubMed  Google Scholar 

  24. Orme S, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endo Metab 1998;83:2730–2734.

    CAS  Google Scholar 

  25. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of growth hormone status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol 1995;42:425–430.

    CAS  Google Scholar 

  26. Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Quart J Med 1993;86:293–293.

    CAS  PubMed  Google Scholar 

  27. Swearingen B, Barker FGII, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endo Metab 1998;83:3419–3426.

    CAS  Google Scholar 

  28. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554–4563.

    Article  CAS  PubMed  Google Scholar 

  29. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur. J Endocrinol 2001;145:137–145.

    CAS  Google Scholar 

  30. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034–3040.

    Article  CAS  PubMed  Google Scholar 

  31. Lundin P, Eden EB, Karlsson FA, Burman P. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: Evaluation with serial MR. AJNR Am J Neuroradiol 1997;18:765–765.

    CAS  PubMed  Google Scholar 

  32. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:5194–5200.

    Article  CAS  PubMed  Google Scholar 

  33. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE. The treatment of de novo acromegalic patients with octreotide-LAR: Efficacy, tolerability and cardiovascular effects. Pituitary 2003;6:11–18.

    Article  CAS  PubMed  Google Scholar 

  34. Lancranjan I, Bruns C, Grass P. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metab 1996;45:67–71.

    CAS  Google Scholar 

  35. Mangupli R, Lisette A, Ivett C, Paul C, de los Rios Victoria C, Luis CJ. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003;6:29–34.

    Article  CAS  PubMed  Google Scholar 

  36. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090–3098.

    Article  CAS  PubMed  Google Scholar 

  37. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779–2786.

    CAS  PubMed  Google Scholar 

  38. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 2003;58:471–481.

    Article  CAS  Google Scholar 

  39. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-4563.

    Article  CAS  PubMed  Google Scholar 

  40. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707–707.

    Article  CAS  PubMed  Google Scholar 

  41. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinol 2002;143:4123–4130.

    Article  CAS  Google Scholar 

  42. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 2003;46:2334–2344.

    Article  CAS  PubMed  Google Scholar 

  43. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89:3027–3032.

    CAS  PubMed  Google Scholar 

  44. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress -parent in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest 1997;100:2386–2392.

    CAS  PubMed  Google Scholar 

  45. van der Haek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638–645.

    Google Scholar 

  46. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28–47.

    Article  CAS  PubMed  Google Scholar 

  47. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140–145.

    Article  CAS  PubMed  Google Scholar 

  48. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003;88:4239–4245.

    CAS  PubMed  Google Scholar 

  49. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003;88:5414–5421.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit, New York University School of Medicine, 550 First Avenue, New York, NY, 10016, USA

    David L. Kleinberg (Professor of Medicine and Director)

Authors
  1. David L. Kleinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kleinberg, D.L. Primary Therapy for Acromegaly with Somatostatin Analogs and a Discussion of Novel Peptide Analogs. Rev Endocr Metab Disord 6, 29–37 (2005). https://doi.org/10.1007/s11154-005-5222-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-005-5222-2

Keywords

Search

Navigation